This site has not been optimised for Internet Explorer due to Microsoft no longer providing support for the browser. Please view this site using another browser such as Google Chrome or Microsoft Edge.
Te Pū rauemi KOWHEORI-19 COVID-19 resource hub

Support for people working in health during the COVID-19 pandemic. Find information about how you can support yourselves and others, including consumers, teams and colleagues which complements and aligns with Ministry of Health resources.

Kia āta kōwhiri Choosing Wisely

The Choosing Wisely campaign seeks to reduce harm from unnecessary and low-value tests and treatment.

Mahi haumaru mō te HA-SAB

Healthcare-associated Staphylococcus aureus bacteraemia (HA-SAB)

Staphylococcus aureus is the most common cause of healthcare-associated bloodstream infections worldwide. Information about how we're working to prevent healthcare-associated Staphylococcus aureus bacteraemia is on this page.

Petri dish with Staphylococcus aureusStaphylococcus aureus (S. aureus) is the most common cause of healthcare-associated bloodstream infections worldwide.

In health settings, S. aureus causes an infection when it enters the bloodstream by means of an existing infection or wound, or during a procedure involving penetration of the skin, such as surgery or the insertion of an intravascular or invasive medical device.

Individuals who develop healthcare-associated Staphylococcus aureus bacteraemia (HA-SAB) infections are more likely to have medical complications, need complex treatment and stay longer in hospital. HA-SAB infections can also result in death.

HA-SAB infections are potentially preventable through the use of infection prevention strategies such as compliance with the ‘5 moments for hand hygiene’, aseptic technique, skin antisepsis before invasive procedures, improved insertion and management of indwelling devices, effective antimicrobial stewardship and regular infection surveillance.

HA-SAB infection surveillance

Continuous ongoing surveillance of healthcare-associated infections, including HA-SAB infections, is an important quality improvement activity that helps to make care safer and guides strategies to improve clinical practice. Surveillance of HA-SAB infection is considered a robust measure of the control of healthcare-associated infections and the quality of infection prevention and control strategies because the identification of S. aureus in a blood culture is rarely considered a contaminant. Many HA-SAB infections are preventable, especially those relating to intravascular devices, which are the most common infection types.

In 2012 Te Tāhū Hauora Health Quality & Safety Commission (Te Tāhū Hauora) endorsed using the rate of HA-SAB infections per 1,000 inpatient days as the outcome marker for Hand Hygiene New Zealand, its national quality improvement programme. The latest outcome marker results are available here

In 2021, Te Tāhū Hauora used data from 2017 to 2021 provided by the then-district health boards to investigate the source of HA-SAB infections in Aotearoa New Zealand public hospitals. Medical devices accounted for most reported HA-SAB infection sources (65 percent), followed by surgical site infection (10 percent) and organ site infection (8 percent). Other sources of HA-SAB infection included medical procedure (7 percent), neutropaenic sepsis (4 percent) and pneumonia (2 percent).

Since 1 July 2022, public hospitals have been required to submit HA-SAB infection data each quarter using a standardised HA-SAB data collection form that captures source details. The first 12 months of HA-SAB surveillance results (1 July 2022 to 30 June 2023) are available here.

This surveillance will detect changes in healthcare-associated infection rates, which will inform quality improvement activities targeting infection prevention measures and best practice related to intravascular and other devices. 

Reducing infections associated with vascular devices

In the 2021 study described above, vascular devices accounted for 96 percent of all devices, comprising central venous catheters (50 percent) and peripheral intravenous catheters (45 percent).

Between 2011 and 2013, Te Tāhū Hauora funded a successful collaborative to reduce the rate of central line associated bacteraemia in Aotearoa New Zealand intensive care units towards zero (< 2 per 1,000 line days). Read the final report for the ‘Target CLAB Zero National Collaborative to Prevent Central Line Associated Bacteraemia’

The infection prevention and control team at Te Tāhū Hauora is currently developing a national quality improvement initiative aimed at reducing infections associated with peripheral intravenous catheters.

Related resources


Guide: Surveillance of healthcare-associated Staphylococcus aureus bacteraemia

Webinar slides: Healthcare-associated Staphylococcus aureus bacteraemia training webinar

Resource: HA-SAB surveillance data form for Te Whatu Ora districts v2.0

Journal article: Sources of healthcare-associated Staphylococcus aureus bacteraemia in New Zealand acute hospitals (October 2022)

Resource: Healthcare-associated infection Severity Assessment Code (SAC) examples 2022–23

Published: 14 Apr 2022 Modified: 24 Nov 2023